UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity

Critical reviews in toxicology, 2005-04, Vol.35 (4), p.325-361

2005

Volltextzugriff (PDF)

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Molecular cancer therapeutics, 2019-12, Vol.18 (12), p.2207-2219

2019

Volltextzugriff (PDF)

Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3‑d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells

Journal of medicinal chemistry, 2015-05, Vol.58 (10), p.4165-4179

2015

Volltextzugriff (PDF)

High glucose and insulin promote O-GlcNAc modification of proteins, including alpha -tubulin

American journal of physiology: endocrinology and metabolism, 2003-02, Vol.284 (2), p.E424-E434

2003

Volltextzugriff (PDF)

Biomarkers of Exocrine Pancreatic Injury in 2 Rat Acute Pancreatitis Models

Toxicologic pathology, 2014-01, Vol.42 (1), p.195-203

2014

Volltextzugriff (PDF)

In Vitro L6 Irritation Assay Predicts Clinical Injection Site Reactions for Small Molecules

Toxicological sciences, 2016-06, Vol.151 (2), p.302-311

2016

Volltextzugriff (PDF)

Application of proteomic technologies in the drug development process

Toxicology letters, 2004-04, Vol.149 (1), p.377-385

2004

Volltextzugriff (PDF)

Withdrawal Assessment Following Subchronic Oral Ketamine Administration in Cynomolgus macaques

Drug development research, 2014-05, Vol.75 (3), p.162-171

2014

Volltextzugriff (PDF)

Peptide-Based In Vitro Assay for the Detection of Reactive Metabolites

Chemical research in toxicology, 2008-04, Vol.21 (4), p.859-868

2008

Volltextzugriff (PDF)

Proteomics: Recent Applications and New Technologies

Basic & clinical pharmacology & toxicology, 2006-05, Vol.98 (5), p.432-441

2006

Volltextzugriff (PDF)

Identification of Novel Peptide Safety Markers for Exocrine Pancreatic Toxicity Induced by Cyanohydroxybutene

Toxicological sciences, 2007-03, Vol.96 (1), p.174-183

2007

Volltextzugriff (PDF)

Evaluation of Two Novel Peptide Safety Markers for Exocrine Pancreatic Toxicity

Toxicological sciences, 2007-03, Vol.96 (1), p.184-193

2007

Volltextzugriff (PDF)

ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Molecular cancer therapeutics, 2020-02, Vol.19 (2), p.325-336

2020

Volltextzugriff (PDF)

Effect of R(+)α-Lipoic acid on pyruvate metabolism and fatty acid oxidation in rat hepatocytes

Metabolism, clinical and experimental, 2004-02, Vol.53 (2), p.165-173

2004

Volltextzugriff (PDF)

Lack of direct mitogenic activity of dichloroacetate and trichloroacetate in cultured rat hepatocytes

Toxicology (Amsterdam), 2005-08, Vol.211 (3), p.220-230

2005

Volltextzugriff (PDF)

Induction of peroxisome proliferation in cultured hepatocytes by a series of halogenated acetates

Toxicology (Amsterdam), 2004-05, Vol.197 (3), p.189-197

2004

Volltextzugriff (PDF)

High glucose and insulin promote O-GlcNAc modification of proteins, including α-tubulin

American journal of physiology: endocrinology and metabolism, 2003-02, Vol.47 (2), p.E424-E434

2003

Volltextzugriff (PDF)

Abstract 3231: Identifying high quality, potent and selective pyrimidinylthienopyrrolone inhibitors of ERK1/2 kinase: LY3214996

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3231-3231

2017

Volltextzugriff (PDF)

Abstract 4973: Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4973-4973

2017

Volltextzugriff (PDF)

Abstract DDT02-02: Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimers with minimal paradoxical activation and activities against BRaf or Ras mutant tumor cells

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.DDT02-02-DDT02-02

2014

Volltextzugriff (PDF)

Epigenetic mechanisms of hepatocarcinogenesis induced by the trichloroethylene metabolites, dichloroacetic acid and trichloroacetic acid

Walgren, Jennie Lenora Everhart

2000

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(22)
Dissertationen
(1)

Sprache

Englisch
(23)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Discovery of 1‑(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3‑d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells

High glucose and insulin promote O-GlcNAc modification of proteins, including alpha -tubulin

Biomarkers of Exocrine Pancreatic Injury in 2 Rat Acute Pancreatitis Models

In Vitro L6 Irritation Assay Predicts Clinical Injection Site Reactions for Small Molecules

Application of proteomic technologies in the drug development process

Withdrawal Assessment Following Subchronic Oral Ketamine Administration in Cynomolgus macaques

Peptide-Based In Vitro Assay for the Detection of Reactive Metabolites

Proteomics: Recent Applications and New Technologies

Identification of Novel Peptide Safety Markers for Exocrine Pancreatic Toxicity Induced by Cyanohydroxybutene

Evaluation of Two Novel Peptide Safety Markers for Exocrine Pancreatic Toxicity

Design, Synthesis, and Biological Evaluation of 3-[4-(2-Hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a Potent, Orally Active, Brain Penetrant Inhibitor of Phosphodiesterase 5 (PDE5)

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Effect of R(+)α-Lipoic acid on pyruvate metabolism and fatty acid oxidation in rat hepatocytes

Lack of direct mitogenic activity of dichloroacetate and trichloroacetate in cultured rat hepatocytes

Induction of peroxisome proliferation in cultured hepatocytes by a series of halogenated acetates

High glucose and insulin promote O-GlcNAc modification of proteins, including α-tubulin

Abstract 3231: Identifying high quality, potent and selective pyrimidinylthienopyrrolone inhibitors of ERK1/2 kinase: LY3214996

Abstract 4973: Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations

Abstract DDT02-02: Identification of LY3009120 as a pan inhibitor of Raf isoforms and dimers with minimal paradoxical activation and activities against BRaf or Ras mutant tumor cells

Epigenetic mechanisms of hepatocarcinogenesis induced by the trichloroethylene metabolites, dichloroacetic acid and trichloroacetic acid

Suchergebnisse filtern